Stopping nucleot(s)ide analogues in non‐cirrhotic <scp>HBeAg</scp> ‐negative chronic hepatitis B patients: <scp>HBsAg</scp> loss at 96 weeks is associated with low baseline <scp>HBsAg</scp> levels

Current guidelines recommend long-term nucleot(s)ide analogue (NA) therapy for patients with HBeAg-negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss.We performed a prospective multi-centre cohort study of stopping NA therapy. Inclusion criteria were HBeAg-negative CHB, the absence of cirrhosis and HBVDNAlower limit of quantification for ≥18 months. We assessed virological and biochemical outcomes including HBsAg loss, as well as NA restart rates, over 96 weeks.In total, 110 patients [62% entecavir (ETV); 28% tenofovir (TDF), 10% other] were enrolled. Median age was 56 years, 57% were male, 85% were Asian, median baseline HBsAg level was 705 (214-2325) IU/ml. Virological reactivation occurred in 109/110 patients, median time to detection was 8 (4-12) weeks, and occurred earlier after stopping TDF versus ETV (median 4 vs. 12 weeks p 0.001). At week 96, 77 (70%) remained off-treatment, 65 (59%) had ALT2&#215; ULN, 31 (28%) patients were in disease remission with HBVDNA2000 IU/ml plus ALT2&#215; ULN and 7 (6%) patients had lost HBsAg. Baseline HBsAg ≤10 IU/ml was associated with HBsAg loss (6/9 vs. 1/101 p 0.001). ALT5&#215; ULN occurred in 35 (32%); ALT flares were not associated with HBsAg loss. There were no unexpected safety issues.Virological reactivation was very common after stopping NA therapy and occurred earlier after stopping TDF versus ETV. The majority of patients had ALT2&#215; ULN at week 96, but only one-third achieved disease remission and HBsAg loss was rare. Very low HBsAg levels at baseline were uncommon but predicted for HBsAg loss and disease remission.